ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s traded shares stood at 0.64 million during the last session, with the company’s beta value hitting 0.18. At the close of trading, the stock’s price was $0.53, to imply a decrease of -5.34% or -$0.03 in intraday trading. The IPA share’s 52-week high remains $2.60, putting it -390.57% down since that peak but still an impressive 39.62% since price per share fell to its 52-week low of $0.32. The company has a valuation of $16.46M, with an average of 0.51 million shares in intraday trading volume over the past 10 days and average of 603.36K shares over the past 3 months.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
After registering a -5.34% downside in the last session, ImmunoPrecise Antibodies Ltd (IPA) has traded red over the past five days. The 5-day price performance for the stock is 0.30%, and 23.28% over 30 days. With these gigs, the year-to-date price performance is 28.76%. Short interest in ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) saw shorts transact 0.69 million shares and set a 0.7 days time to cover.
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
Looking at statistics comparing ImmunoPrecise Antibodies Ltd share performance against respective industry, we note that the company has outperformed competitors. ImmunoPrecise Antibodies Ltd (IPA) shares are -37.40% down over the last 6 months, with its year-to-date growth rate higher than industry average at 65.38% against 25.20%. The rating firms project that company’s revenue will grow 0.92% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 6.58M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 6.77M.Earnings reports from the last fiscal year show that sales brought in 6.22M and 6.46M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 5.85% before jumping 4.81% in the following quarter.
IPA Dividends
ImmunoPrecise Antibodies Ltd has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
ImmunoPrecise Antibodies Ltd insiders hold 12.06% of total outstanding shares, with institutional holders owning 6.58% of the shares at 7.48% float percentage. In total, 6.58% institutions holds shares in the company, led by INGALLS & SNYDER LLC. As of 2024-06-30, the company held over 1.3 million shares (or 5.0209% of shares), all amounting to roughly $1.31 million.
The next major institution holding the largest number of shares is RENAISSANCE TECHNOLOGIES LLC with 63910.0 shares, or about 0.2477% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $64549.0.
Going by data provided on Nov 30, 2024 , Fidelity NASDAQ Composite Index Fund holds roughly 10.67 shares. This is just over 0.04% of the total shares, with a market valuation of $5655.0
